Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple score decide when to start ECMO and save more lives?

NCT ID NCT05412303

Knowledge-focused Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study looks at whether a score based on heart-support medications (the vasoactive-inotropic score, or VIS) can help doctors decide the best time to start ECMO in patients who develop severe heart failure after cardiac surgery. Researchers will review medical records from nearly 2,800 adults who had ECMO placed in the operating room after heart surgery. The goal is to see if higher VIS scores are linked to better outcomes when ECMO is started early.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could provide doctors with a clear, objective tool to decide when to start ECMO, potentially saving more lives after heart surgery.
What could go wrong
This is an observational study, not a controlled trial, so it can show associations but not prove cause and effect. The score may not work as well in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,769 people

The number who actually took part.

Started

Jan 2019

Finished

Dec 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Post cardiotomy cardiogenic shock

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age over 18 years * Cardiac surgery with cardiopulmonary bypass * Post cardiotomy cardiogenic shock * ECMO-VA implanted in OR Exclusion Criteria: * LVAD * Heart transplantation * Incomplete data in relation to outcomes * Cardiac arrest

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Emco-va are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiogenic shock

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Emco-va

Contacts and locations

Locations

  • Chu Dijon Bourogne

    Dijon, 21000, France